Guggenheim Reiterates Buy Rating on ProMIS Neurosciences, Inc. (PMN)

Market Context

ProMIS Neurosciences, Inc. operates in the Healthcare sector. The stock currently trades at $14.06 with a market capitalization of $11.3M. The stock has declined 41.1% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ProMIS Neurosciences, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ProMIS Neurosciences, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Related Tools: Analyst Ratings Dashboard | View PMN Stock Page